Dyno Therapeutics, Inc.

As #RareDiseaseWeek wraps up, I’m reflecting on how communities advance genetic medicines. Progress in rare disease therapeutic development doesn't happen in isolation. It takes researchers, technologists, physicians and patient advocates across the community working in concert to create the right treatment, show that it benefits patients, and make these medicines accessible. Today, most rare diseases patients have no available treatments that address the genetic cause of their disease. New technologies, including AI and gene therapy, are starting to change that, creating genetic agency for patients to help them live a healthier life. Last November, the inaugural Genetic Agency Technology Conference (GATC) brought 200 leaders across fields together in Boston to share their insights. This is what high-tech collaboration looks like, at scale. If you’d like to build technologies that empower patients with #GeneticAgency, we hope you join our GATC events this year. To catch more #GATC25 content or subscribe for updates, check out the new @Dyno_Tx YouTube Channel: @Dyno_Tx/videos" target="_blank" rel="nofollow noopener">youtube.com/@Dyno_Tx/videos

🌍 Revolutionizing Drug Discovery with AI + NVIDIA BioNeMo 🆕 The expansion announced at #JPM26 includes: - New open models like RNAPro (RNA structure prediction) & ReaSyn v2 (AI-driven synthesis design) - Powerful tools like BioNeMo Recipes & nvMolKit to scale model training and molecular discovery - Seamless integration of agentic and physical AI to accelerate science 📦 Unpack the details nvda.ws/45PyuwN